ZYBERNO
Stock Report
Updated Sep 1, 2026

Jade Biosciences, Inc. (JBIO)

Healthcare • NASDAQ

$20.84

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Jade Biosciences, Inc. (JBIO) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-60.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-41.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Jade Biosciences, Inc. (JBIO) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, JBIO generated -$56.87M in Owner Earnings. Capital was deployed as follows: $65.00M paid as dividends, $142.00K invested in capital expenditures. Reinvestment rate: -0.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:20.84
Market Cap:$1.27B

Valuation Multiples (2)

P/B Ratio:2.89x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.17B

Price Action & Momentum (3)

Momentum Percentile:94 / 100
% of 52-Week High:74.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-56.2%
Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.1%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$17.13
Dividend Yield:5.1%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:21.9%
Latest Earnings Filed:2026-08-10
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:14.93x
Quick Ratio:14.93x
Cash Ratio:3.40x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:439,681,000.00
Cash And Cash Equivalents:107,250,000.00
Long Term Debt:$628.00K
Net Debt:-$106.39M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$184.74M

Bottom Line Performance (3)

-$188.89M
Income Before Tax:-$55.75M
Ebitda Ttm:-184,707,000.00

Operating Expenses (5)

Operating Expenses:184,738,000.00
R And D Expense:136,612,000.00
Sga Expense:28,046,000.00
Income Tax Expense:$31.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$472.11M
Current Assets:$471.25M
Ppe Net:144,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:32,198,000.00
Current Liabilities:31,570,000.00
Long Term Debt:$628.00K
Short Term Debt:$231.00K

Equity & Capital (3)

Equity:$439.92M
Retained Earnings:-$270.52M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:6,579,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:13,606,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$116.39M-$116.53M

Investment Activities (2)

Investing Cash Flow:-$8.47M
Capital Expenditures Ttm:142,000.00

Financing Activities (3)

Financing Cash Flow:-$795.00K
Dividends Paid Ttm:65,000,000.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:23,942,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:31,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.57
-$3.57
Earnings Per Share Ttm:-$3.09

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.55

Book Value & Capital (2)

Book Value Per Share:$7.21
Cash Per Share:1.76

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$56.87M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.1%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):18.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:JBIO
Company Name:Jade Biosciences, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:61.05M
Shares Outstanding Basic:61.05M
Shares Outstanding Diluted:61.05M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 06:09:11 UTC
Data Timestamp:2026-09-01T06:09:11.529671
Scroll to Top